Clinical Trial Update: UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating an allogeneic UCAR T-cell therapy targeting CD19 and BCMA for relapsed/refractory Autoimmune Hemolytic Anemia is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• UCAR T-cell Therapy (CD19/BCMA) (Allogeneic CAR-T cell therapy targeting CD19 and BCMA)

Snippet

Sponsor: The Second Hospital of Anhui Medical University | Conditions: AIHA - Warm Autoimmune Hemolytic Anemia, UCART | EARLY_Phase 1 | Status: RECRUITING